1. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma
- Author
-
Matthaios Speletas, Smaragda Effraimidou, Dimitrios Kapetanos, Evgenia Verrou, Anastasia Banti, Charalambos Kartsios, Eirini Katodritou, Evangelos Terpos, John Christakis, and Konstantinos Zervas
- Subjects
Adult ,Erythrocyte Indices ,Male ,medicine.medical_specialty ,Erythrocytes ,Adolescent ,Lymphoma ,Anemia ,Hematocrit ,Gastroenterology ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,Erythropoiesis ,Erythropoietin ,Multiple myeloma ,Aged ,Aged, 80 and over ,chemistry.chemical_classification ,Hematology ,Anemia, Iron-Deficiency ,medicine.diagnostic_test ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Recombinant Proteins ,chemistry ,Transferrin ,Immunology ,Hematinics ,Female ,Multiple Myeloma ,business ,Biomarkers ,medicine.drug - Abstract
The aim of the study was to evaluate the role of hypochromic erythrocytes (HYPO%) compared to “traditional” and novel markers of iron status and erythropoiesis in recognizing iron-restricted erythropoiesis (IRE) and predicting response to erythropoietin (rHuEPO) in anemic patients with myeloma and lymphoma. Forty-one newly diagnosed patients who received epoetin-beta at a subcutaneous weekly dose of 30,000 IU for 6 weeks were studied. Response to rHuEPO was observed in 27 patients (65.8%). Twelve non-responders received, additionally, 200 mg of IV iron sucrose, weekly, for 4 weeks. Evaluation of markers was performed at baseline and on weeks 1, 2 and 6 for all patients and also on weeks 7–10 for non-responders to rHuEPO. Baseline HYPO%, at a cut-off value of
- Published
- 2007
- Full Text
- View/download PDF